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Purpose: We report that primary infertility and hypergonadotropic hypogonadism in young patients may be caused by
testicular amyloidosis and it is associated with the presence of a mutation in the apoA-I gene, resulting in the replacement
of proline for leucine at residue 75 of the protein.
Materials and Methods: Ten patients presenting with infertility, gynecomastia, decreased libido, erectile dysfunction or a
family history of amyloidosis underwent clinical evaluation, hormone assays, semen analysis, ultrasonographic investigation
of the testicles, testicular biopsy and DNA sequencing of the apoA-I gene.
Results: All patients showed azoospermia and 9 had increased testicular volume. Massive amyloid deposition was observed
in all testicular biopsies and the apoA-I mutation of replacement of proline for leucine at residue 75 of the protein was noted.
Five patients showed hypergonadotropic hypogonadism and 5 had normal testosterone values with high gonadotropin levels.
Conclusions:Nonobstructive azoospermia and macro-orchidism with or without hypogonadismmay be caused by hereditary
apoA-I amyloidosis in young patients. Testicular amyloidosis can be the first manifestation of this systemic disease. Specific
staining for amyloid deposits and genetic analysis of apoA-I mutations are recommended in young, infertile patients with
macro-orchidism. Finally, surveillance in asymptomatic mutation carriers is suggested to evaluate the opportunity to
implement sperm retrieval and start androgen replacement therapy when necessary.
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ystemic amyloidosis consists of a group of diseases
characterized by the progressive extracellular deposi-
tion of soluble plasma proteins as insoluble fibrils,
disrupting tissue integrity, which leads to organ dysfunc-
tion.1 Of the diseases AL and AA are the most frequent.
Acquired AL is generated by the deposition of Ig light-chain
fragments produced by clonal plasma cells, AA is a long-
term complication of several chronic inflammatory condi-
tions and some systemic types of amyloidosis are inherited
and present as autosomal dominant diseases. In hereditary
amyloidosis amyloid fibrils derive from a mutated form of 1
of certain proteins, including transthyretin, lysozyme,
apoA-I, apolipoprotein A-II, fibrinogen A chain, cystatin C
and gelsolin.
Clinically systemic amyloidosis is characterized by renal,
heart, liver and peripheral nerve involvement that is iso-
lated or variably associated, leading to progressive organ
failure and ultimately to death. Testicular amyloid localiza-
tion, resulting in azoospermia and hypogonadism, is rarely
observed in the context of AL,2 while it is more frequently
described in AA, especially in patients with familial Medi-
terranean fever.3,4 Testicular amyloidosis as a first sign of
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344systemic amyloidosis has been occasionally reported, mani-
festing as hypogonadism, sterility and macro-orchidism.5–7
However, in most of these cases it was never formulated as
a diagnosis based on the biochemical nature of the amyloid
deposits. Schrepferman et al described secondary infertility
due to testicular amyloid deposition as the only clinical
finding in a patient heterozygous for an apoA-I variant.8
Similarly testicular biopsy showed amyloid deposits several
years before the occurrence of severe amyloid cardiomyopa-
thy in a patient carrying the leucine 174 serine mutation of
apoA-I.9
ApoA-I, the major component of high density lipoproteins,
can cause systemic amyloidosis at the presence of specific
amino acid replacements. A total of 12 amyloidogenic apoA-I
variants have been identified to date.10 The natural history of
the disease consists of progressive liver and kidney involve-
ment with restrictive cardiomyopathy observed in some vari-
ants. We recently referred to an amyloidogenic variant of
apoA-I associated with a predominantly sporadic presenta-
tion, in which the leucine residue at position 75 is replaced
by proline (Leu75Pro).11 In the first 2 series of patients in
whom the diagnosis was confirmed by genetic and immuno-
histochemical analyses surgically treated Gyn was reported
in a few,11,12 suggesting testicular localization of the dis-
ease. However, no additional studies were performed in
these subjects.
To our knowledge we report for the first time a detailed
characterization of apoA-I testicular amyloidosis in a novel
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INFERTILITY AND HYPOGONADISM IN ApoA-1 AMYLOIDOSIS 345series of patients. Furthermore, this proves that the early
deposition of amyloid in the testes leading to infertility is a
peculiar feature of this form of the disease.
MATERIALS AND METHODS
Of 1,400 infertile men examined in a 13-year period at the
Department of Endocrinology at University of Brescia 10
were found to have testicular amyloidosis due to the hered-
itary Leu75Pro mutation of Apo A-I. In all patients the
testicle was the first or single organ involved. Mean patient
age  SD was 35.7  6.3 years (range 29 to 45) at diagnosis
and all were included in the study. Patients were examined
due to rLib, ED, gynecomastia, infertility or a family history
of amyloidosis that was isolated or variably associated (see
table).
All patients underwent testicular biopsy after collecting
the personal and family medical history as well as physical
examination of the genitals and breast, ultrasonographic
investigation of the abdomen and testicles, and semen anal-
ysis. Blood samples for hormonal assays, hepatic and renal
function parameters, and DNA sequencing of the apoA-I
gene were also taken.
For the medical history particular attention was given to
libido, erectile function, past urological pathologies, infertil-
ity, the number of children and patient age at conception.
Assessment of the hormonal profile was performed at 9:00
a.m. with the patient fasting. The parameters measured at a
centralized laboratory were LH, FSH, SHBG, T and calcu-
lated fT. Vermeulen’s formula was used to calculate fT ac-
cording to published criteria.13
At ultrasonographic investigation testicular volume was
calculated with the Taskinen and Schiff formula, 0.71 
length  width  depth.14 Echographic examinations were
performed by the same physician using a 7 to 12 MHz linear
multifrequencing Sequoia Siemens™ instrument. In the lit-
erature a testicular volume of between 15 and 25 ml is consid-
ered normal.15 All data are presented as the mean  SD.
Semen analysis was performed by the same specialist
according to the WHO manual definition. Histological eval-
uation was done by the same physician according to stan-
dard techniques. The search for amyloid deposits was done
by Congo red staining, followed by microscopic examination
under polarized light. Immunohistochemical characteriza-
tion of amyloid deposits was made on paraffin embedded
sections using a panel of antibodies against  and 
chains, serum amyloid-A, fibrinogen and apoA-I (Dako,
Milan, Italy). This last reaction was visualized with the
alkaline phosphatase RED method.
All patients provided written informed consent and the
study was approved by the Institutional Review Board. Ge-
netic testing was performed on DNA extracted from periph-
eral blood using standard procedures. Screening for apoA-I
mutations was done by direct sequencing of polymerase
chain reaction amplified fragments, as previously de-
scribed.11
RESULTS
The table lists patient initial clinical characteristics. Previ-
ous testicular pathologies were present in 3 cases, including
varicocele, orchio-epididymitis and funicular torsion, respec-
tively. Two patients had a family history of amyloidosis. TwoN 1
INFERTILITY AND HYPOGONADISM IN ApoA-1 AMYLOIDOSIS346patients had fathered a child before diagnosis and 1 had
fathered 2 children at the ages indicated (see table).
At physical examination 1 or 2 testicles appeared smooth,
markedly enlarged and toughened in patients 1 to 9. These
findings were confirmed by a homogeneous solid appearance
on ultrasound with a mean volume of 31.4 6.7 ml (range 19
to 39) for the right testicle and 32.0 9.3 ml (range 19 to 44)
for the left testicle. No additional pathological findings were
revealed by abdominal ultrasound screening.
All patients were completely azoospermic. Patient 2 un-
derwent previous semen analyses due to infertility, which
revealed normospermia (32  106 spermatozoa per ml)
23 months before the diagnosis of amyloidosis and severe
oligospermia (60  103 spermatozoa per ml) 6 months pre-
viously.
Hepatic and renal function was normal in all patients.
Hypergonadotropic hypogonadism was present in patients 6
to 10 with low androgen levels, including T 1.6  1.1 ng/ml
(normal at our laboratory 3.5 to 9) and fT 21.6  9.7 pg/ml
(normal 75 to 124), and high gonadotropin values, including
LH 33.8 8.7 mU/ml (normal 0.5 to 6) and FSH 59.7  22.4
mU/ml (normal 0.5 to 6). In contrast, patients 1 to 5
showed normal androgen values with T 4.1  0.2 ng/ml
and fT 84.2  14.5 pg/ml but increased levels of LH and
FSH at 13.7  3.9 and 25.6  6.5 mU/ml, respectively. All
except patient 9 had SHBG concentrations within the
normal range (13 to 71 nMol/l).
Histological analysis of testicular biopsies showed abun-
dant deposits of amorphous eosinophilic material, strongly
suggestive of amyloid (part A of figure). Congo red staining
confirmed the presence of pathognomonic apple-green bire-
fringence under polarized light. Amyloid deposits were
found around the basement membrane of the seminiferous
tubules, narrowing or obstructing the lumen in any case.
Patients 3 to 10 had a germinal epithelium that was com-
pletely replaced by amyloid without Sertoli’s cells. Patients
1 and 2 presented with mixed tissue morphology, showing
areas with complete replacement of the germinal epithelium
scattered with tubules with only Sertoli’s cells as well as
areas at all stages of spermatogenesis.
Amyloid deposits were also found in the interstitium, in
the walls of arteries, capillaries and veins. They increased
wall thickness with a decreased lumen in all patients, lead-
ing to complete obstruction in some men. No Leydig cells
were seen in the biopsies of patients 6 to 8, who had hypo-
A, testicular biopsy reveals massive peritubular deposition of amor-
phous material with complete loss of germinal epithelium (yellow
arrows). Interstitial amyloid deposits are visible focally (white ar-
rows). H & E, reduced from 25. B, immunohistochemical analysis
of testicular biopsy by anti-Apo A-I antibody shows intense immuno-
staining of peritubular and interstitial amyloid deposits, in particular
focal interstitial deposits (yellow arrows). Reduced from 25.gonadism. Patient 9 with hypogonadism and patients 2 and
4 with normal testosterone levels showed only a few Leydig
cells without precise tissue organization. Finally, patients 1,
3 and 5 with normal testosterone and patient 10 with hypo-
gonadism had few aggregates of Leydig cells, which retained
normal tissue architecture. At immunohistochemical analy-
sis amyloid deposits were intensively and specifically immu-
noreactive with anti-apoA-I antibody but not with the other
antibodies tested (part B of figure).
Genetic analysis performed through direct DNA sequenc-
ing showed that all 10 patients were heterozygous for a
thymine to cytosine transition at nucleotide 1772 of the
apoA-I gene, resulting in a leucine to proline amino acid
replacement at residue 75 of the mature protein. No patients
had different apoA-I variants, a normal apoA-I genotype or
other sequence variations.
DISCUSSION
The current study demonstrates that testicular failure is a
typical finding in hereditary apoA-I amyloidosis, especially
in association with the Leu75Pro variant of this protein.
Testicular involvement can be the first or the single mani-
festation of the disease and it evolves with time.
To our knowledge this is the first series of patients with
apoA-I amyloidosis in which the clinical and pathological
basis of testicular amyloid involvement was characterized in
detail. These data strengthen and expand previous descrip-
tions of single patients in whom testicular failure was re-
ported in the medical history several years before a diagno-
sis of cardiac9 or visceral11,12 apoA-I amyloidosis was made.
The Leu75Pro mutation of the apoA-I gene leads to
asymptomatic, long-standing, mild to moderate renal fail-
ure, and increased alkaline phosphatase and -glutamyl-
transferase levels.11,12 Compared to other variants this is
associated with a mild phenotype due to the slower progres-
sion of kidney and liver deposits. The lack of a family his-
tory, advanced patient age at renal or hepatic biopsy and the
limited evidence of disease related mortality strengthen this
view. The current study proves that this disease occurs
earlier than expected and it may be responsible for the
dramatic impairment of fertility from the third decade of
life. ApoA-I amyloidosis should be suspected in patients with
azoospermia, a normal or decreased testosterone level and
normal or high testicular volume even in the absence of an
informative family history.
The frequency of this rare genetic condition still remains
to be defined. A possible founder effect likely justifies the
high incidence in our population. However, the same variant
was reported in a patient with a different ethnic back-
ground, suggesting more widespread distribution.16
Our study shows the characterization of the pathological
basis for testicular apoA-I amyloidosis and the possible mo-
lecular mechanisms of this disease. Biopsies revealed a ger-
minal epithelium that was completely replaced by amyloid
fibrils or Sertoli’s cells only. Amyloid deposits are also
present in the vessel walls, leading to narrowing or obstruc-
tion, and in the interstitium with partial or complete Leydig
cell substitution. In patients 1 and 2 there coexisted areas of
complete germinal epithelium replacement, areas with Ser-
toli’s cells only and areas at all stages of spermatogenesis.
Repeat semen analyses in patient 2 during the 23 months
before diagnosis revealed rapid evolution from normosper-
INFERTILITY AND HYPOGONADISM IN ApoA-1 AMYLOIDOSIS 347mia to oligospermia and azoospermia. The progressive im-
pairment of spermatogenic function is due to the gradual
deposition of amyloid, which causes parenchymal replace-
ment, and it seems to reflect the mixed histological profile.
Our findings agree with previous results, reflecting similar
observations in AA and AL.4,17
To date different hypotheses have been formulated on the
mechanisms that cause the impairment of spermatogenic
function by amyloid. A hypothesis is that azoospermia can
be due to the obliteration of intratesticular canaliculi or to
the disruption of sperm production through a direct effect on
the seminiferous tubules by amyloid deposits.3,4 Özdemir
et al proposed that the narrowing and obstruction of vessels
may cause long-term hypoxia, leading to disruption of the
germinal epithelium with spermatogenic arrest.17 Vascular
compression was proposed to be caused by amyloid deposi-
tion in the vessel tunica propria or by interstitial fluid from
damaged and more permeable vessels.
In all patients testicular biopsies showed increased vessel
wall thickness and partial or complete replacement of the
germinal epithelium by amyloid deposits, indicating that
tubular and vascular obstructions are probably the end
stages of the same process. Amyloid fibrils were also found
in the interstitium, causing partial or complete Leydig cell
replacement. This explains the low level of T and fT, and the
high level of gonadotropins in patients 6 to 10. In patients 1
to 5, in whom Leydig cells appeared less disrupted, high
FSH and LH values were able to maintain normal testoster-
one levels, indicating early and subclinical gonadic dysfunc-
tion. Histological findings also support clinical and hor-
monal data, suggesting that testicular failure results from
progressive parenchymal replacement by amyloid deposits,
first compromising spermatogenesis in 100% of the patients
and then endocrine function in 50%.
In the literature it is known that the onset of hypergonad-
otropic hypogonadism can follow nonobstructive azoosper-
mia in primary testicular failure.15 Tubular dysfunction
may occur with normal testosterone production initially due
to higher sensitivity to damage to seminiferous tubules
rather than Leydig cells.18
In this series testicular volume was normal or high com-
pared to that in other pathological conditions associated
with impaired spermatogenesis that lead to micro-orchid-
ism, including primary hypogonadism due to congenital ab-
normalities, Klinefelter’s syndrome, myotonic dystrophy,
cryptorchidism and abnormal karyotypes. These findings
confirm previous case report data on the size of amyloidotic
testicles.5–8,19 Briefly, testicular involvement appears to be an
early and clinically relevant feature of apoA-I amyloidosis com-
pared to other systemic forms of the disease.
In the literature histological data indicate a similar dis-
tribution of amyloid deposits in the testicular parenchyma
apart from the protein precursor involved.17 To our knowl-
edge the reasons for the peculiar tissue targeting of apoA-I
amyloid deposits are presently unknown. In particular no
association with any previous testicular pathology was
found. We hypothesize that the high concentration of the
amyloid precursor in the testicular extracellular milieu
might be due to the specific functional and metabolic prop-
erties of apoA-I. In fact, this protein has a key role in cho-
lesterol trafficking, particularly in steroidogenic tissues.20ApoA-I removes excess cholesterol from Sertoli’s cellsthrough the adenosine triphosphate-binding cassette trans-
porter-A1 receptor and it supplies cholesterol to steroido-
genic cells through the scavenger receptor class B type-I. It
is possible that conformational changes occurring during the
process of lipid exchange might contribute to the proteolytic
remodeling of the protein when mutated, promoting the
generation of N-terminal peptides and triggering the fibril-
logenetic process.
CONCLUSIONS
This study clearly points out that infertility with or without
complete hypogonadism is an early and clinically relevant
finding in hereditary Apo A-I amyloidosis, particularly in
association with the Leu75Pro variant of this protein. Tes-
ticular involvement is associated with normal or high testic-
ular volume and it may be the first or single manifestation of
disease in young patients. Dramatic impairment of fertility
may occur from the third decade of life. Progression of sper-
matogenic deterioration to complete azoospermia may hap-
pen in about 2 years. Thus, semen analysis should be ad-
vised annually in young, asymptomatic carriers of the
mutation, whereas testicular biopsy is suggested at the on-
set of spermatogenic impairment to increase the chance of
sperm retrieval. Moreover, evaluation of gonadic function
should be done annually, also in older patients with known
renal or hepatic damage, to start testosterone administra-
tion when necessary. In cases of infertility, nonobstructive
azoospermia and macro-orchidism with complete or subclin-
ical hypogonadism apoA-I amyloidosis must be suspected
even in the absence of a significant family history.
Abbreviations and Acronyms
AA  reactive amyloidosis
AL  Ig light-chain amyloidosis
Apo  apolipoprotein
ED  erectile dysfunction
FSH  follicle-stimulating hormone
fT  free testosterone
Gyn  gynecomastia
Inf  infertility
Leu75Pro  leucine 75 proline
LH  luteinizing hormone
rLib  decreased libido
SHBG  sex hormone binding globulin
T  total testosterone
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